Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W A Hall

Showing results (111-120 of 115) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 115 results.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 16, 2026
Does Overall Treatment Time Impact Toxicity and Clinical Outcomes After Magnetic Resonance Imaging-Guided Stereotactic Body Radiotherapy to the Prostate? An evaluation of the Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac RepositoryR L Westley, L A Daamen, F R Teunissen, et al.
Practical Radiation Oncology|August 23, 2025
Liver metastases treated with MRI-guided SBRT: Outcomes of tolerability, acute toxicity and quality of life from the MOMENTUM studyMd J E Peltenburg, R Westley, L A Daamen, et al.
Oncogene|November 27, 2013
Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancerW A Hall, A V Petrova, L E Colbert, et al.
Medrxiv : the Preprint Server for Health Sciences|May 7, 2024
ALLIANCE A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancerJ Alvarez, Q Shi, A Dasari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2025
Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trialsA Dal Pra, P Ghadjar, H M Ryu, et al.
Pageof 12

Showing results (111-120 of 115) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 115 results.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 16, 2026
Does Overall Treatment Time Impact Toxicity and Clinical Outcomes After Magnetic Resonance Imaging-Guided Stereotactic Body Radiotherapy to the Prostate? An evaluation of the Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac RepositoryR L Westley, L A Daamen, F R Teunissen, et al.
Practical Radiation Oncology|August 23, 2025
Liver metastases treated with MRI-guided SBRT: Outcomes of tolerability, acute toxicity and quality of life from the MOMENTUM studyMd J E Peltenburg, R Westley, L A Daamen, et al.
Oncogene|November 27, 2013
Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancerW A Hall, A V Petrova, L E Colbert, et al.
Medrxiv : the Preprint Server for Health Sciences|May 7, 2024
ALLIANCE A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancerJ Alvarez, Q Shi, A Dasari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2025
Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trialsA Dal Pra, P Ghadjar, H M Ryu, et al.
Pageof 12